Observational findings reveal that intranasal ketamine may reduce opioid use in cancer pain, suggesting careful patient selection is needed due to adverse effects.
Intranasal ketamine may reduce opioid requirements in cancer-related pain, but adverse effects can limit tolerability. Future research should identify high-risk patients and develop risk mitigation strategies.
No takes yet. Share an insight, caveat, or question.
Welsh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: